هل الببتيدات آمنة: ما تقوله الأبحاث السريرية

Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Informational

ما هي الببتيدات وكيف تعمل في الجسم؟ دليل شامل

الببتيدات سلاسل قصيرة من الأحماض الأمينية تؤدي أدواراً حيوية في التمثيل الغذائي والمناعة وإصلاح الأنسجة. يشرح هذا الدليل بنيتها وآليات عملها وتطبيقاتها العلاجية المعتمدة في المنطقة العربية وفق لوائح الهيئة العامة للغذاء والدواء (SFDA) ووزارة الصحة الإماراتية (MOHAP).

Ambrosia Biosciences Raises $100M to Develop Small-Molecule GLP-1 Pills That Could Replace Injections

Colorado-based Ambrosia Biosciences closed an oversubscribed $100M Series B to advance oral small-molecule GLP-1 therapies for obesity, aiming to move beyond peptide-based injections like Ozempic and Mounjaro with a Phase 1 trial of its lead candidate.

Clinical

APhA 2026: Pharmacists Say GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease

At the 2026 American Pharmacists Association Annual Meeting in Los Angeles, experts presented evidence that GLP-1 receptor agonists have expanded far beyond diabetes into cardiovascular, liver, and kidney disease — challenging pharmacists to keep pace.

Daiichi Sankyo Partners With Meddenovo to Use AI for Designing Cyclic Peptide Drug Candidates

Japanese pharma giant Daiichi Sankyo has partnered with AI drug design company Meddenovo to accelerate the discovery of cyclic peptide-based therapeutics using AI and physical computational approaches, signaling growing industry interest in the peptide modality beyond GLP-1.

Neuland Laboratories to Open $30M Commercial Peptide Manufacturing Facility in India

India-based CDMO Neuland Laboratories will open a commercial-scale peptide manufacturing facility at its Hyderabad campus in summer 2026, adding 6,370 liters of synthesis capacity to meet surging global demand driven by the GLP-1 boom.